Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Cumulative Risks of Developing Extrapyramidal Signs, Psychosis, or Myoclonus in the Course of Alzheimer's Disease

Cumulative Risks of Developing Extrapyramidal Signs, Psychosis, or Myoclonus in the Course of... Abstract • Cumulative risks of developing extrapyramidal signs, psychosis, and myoclonus in the course of Alzheimer's disease (AD) were estimated in 72 patients with probable AD by the Kaplan-Meier survival method. The cumulative risk functions were found to increase at different rates for different signs as AD progressed. Comparisons of the cumulative risk functions revealed that in the early stages of AD, extrapyramidal signs and psychosis were more likely to develop than myoclonus. As AD progressed, the risk of developing myoclonus became as great as that of developing the other two signs. This study suggests that extrapyramidal signs, psychosis, and myoclonus represent developmental features that mark the progression of AD, rather than indicators of disease subtypes. The estimated cumulative risk functions set a reasonable expectation for the timing and likelihood of the emergence of the clinical signs. This, in turn, might aid in disease prognosis because the biological bases of these signs have been established and they have been shown to be predictive of other markers of disease course. References 1. Mayeux R, Stern Y, Spanton S. Heterogeneity in dementia of the Alzheimer's type: evidence of subgroups . Neurology . 1985;35:453-461.Crossref 2. Kaye JA, May C, Daly E, et al. Cerebral fluid monoamine markers are decreased in dementia of the Alzheimer's type with extrapyramidal features . Neurology . 1988;38:554-557.Crossref 3. Chui HC, Teng EL, Henderson VW, Moy AC. Clinical subtypes of dementia of the Alzheimer type . Neurology . 1985;35:1544-1550.Crossref 4. Drevets WC, Rubin EH. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer's type . Biol Psychiatry . 1989;25:38-48.Crossref 5. Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer's disease . Am J Psychiatry . 1989;146:577-587. 6. Duffy P, Mayeux R, Kupsky W. Familial Alzheimer's disease with myoclonus and spongy change . Arch Neurol . 1988;45:1097-1103.Crossref 7. Kaye JA, May C, Atack JR, et al. Cerebrospinal fluid neurochemistry in the myoclonic subtype of Alzheimer's disease . Ann Neurol . 1988;24:647-650.Crossref 8. Stern Y, Mayeux R, Sano M, Hauser WA, Bush T. Predictors of disease course in patients with probable Alzheimer's disease . Neurology . 1987;37:1649-1653.Crossref 9. Stern Y, Mayeux R, Hesdorffer D, Sano M. Measurement and prediction of functional capacity in Alzheimer's disease . Neurology . 1990;40:8-14.Crossref 10. Stern Y, Mayeux R, Chen JY, Sano M. Predictors of mortality in Alzheimer's disease . Ann Neurol . 1989;26:132. 11. Kaplan EL, Meier P. Nonparametricestimation from incomplete observations . J Am Stat Assoc . 1958;53:457-481.Crossref 12. Diagnostic and Statistical Manual of Mental Disorders-III-Revised . Washington, DC: American Psychiatric Association; 1986. 13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease . Neurology . 1984;34:939-944.Crossref 14. Fahn S, Marsden C, Calne D, et al. Recent Developments in Parkinson's Disease . Florham Park, NJ: Macmillan Healthcare Information; 1987;2:153-163. 15. Sano M, Stern Y, Mayeux R, Hartman S, Devanand DP. A standardized technique for establishing the onset symptoms of probable Alzheimer's disease J Exp Clin Neuropsychol . 1987;9:65. Abstract. 16. Lee E. Statistical Methods for Survival Data Analysis . Belmont, Calif: Lifetime Learning Publications; 1980. 17. SAS User's Guide. Statistics. 5 ed. Cary, NC: SAS Institute Inc; 529-557. 18. Rothman KJ. Modern Epidemiology . Boston, Mass: Little Brown & Co Inc; 1986. 19. Ditter SM, Mirra SS. Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients . Neurology . 1987;37:754-760.Crossref 20. Molsa PK, Marttila RJ, Rinne UK. Extrapyramidal signs in Alzheimer's disease . Neurology . 1984;34:1114-1116.Crossref 21. Pearce J. The extrapyramidal disorder of Alzheimer's disease . Eur Neurol . 1974;12:94-103.Crossref 22. National Institutes of Health Conference. Alzheimer's disease: clinical and biological heterogeneity . Ann Intern Med . 1988;109:298-311.Crossref 23. Breitner JCS, Murphy EA, Silverman JM, Mohs RC, David KL. Age-dependent expression of familial risk in Alzheimer's disease . Am J Epidemiol . 1988;128:536-548. 24. Farrer LA, Myers RH, Cupples LA, et al. Transmission and age-at-onset patterns in familial Alzheimer's disease: evidence for heterogeneity . Neurology . 1990;40:395-403.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Neurology American Medical Association

Cumulative Risks of Developing Extrapyramidal Signs, Psychosis, or Myoclonus in the Course of Alzheimer's Disease

Loading next page...
 
/lp/american-medical-association/cumulative-risks-of-developing-extrapyramidal-signs-psychosis-or-cru9tZ8dSu
Publisher
American Medical Association
Copyright
Copyright © 1991 American Medical Association. All Rights Reserved.
ISSN
0003-9942
eISSN
1538-3687
DOI
10.1001/archneur.1991.00530230049020
Publisher site
See Article on Publisher Site

Abstract

Abstract • Cumulative risks of developing extrapyramidal signs, psychosis, and myoclonus in the course of Alzheimer's disease (AD) were estimated in 72 patients with probable AD by the Kaplan-Meier survival method. The cumulative risk functions were found to increase at different rates for different signs as AD progressed. Comparisons of the cumulative risk functions revealed that in the early stages of AD, extrapyramidal signs and psychosis were more likely to develop than myoclonus. As AD progressed, the risk of developing myoclonus became as great as that of developing the other two signs. This study suggests that extrapyramidal signs, psychosis, and myoclonus represent developmental features that mark the progression of AD, rather than indicators of disease subtypes. The estimated cumulative risk functions set a reasonable expectation for the timing and likelihood of the emergence of the clinical signs. This, in turn, might aid in disease prognosis because the biological bases of these signs have been established and they have been shown to be predictive of other markers of disease course. References 1. Mayeux R, Stern Y, Spanton S. Heterogeneity in dementia of the Alzheimer's type: evidence of subgroups . Neurology . 1985;35:453-461.Crossref 2. Kaye JA, May C, Daly E, et al. Cerebral fluid monoamine markers are decreased in dementia of the Alzheimer's type with extrapyramidal features . Neurology . 1988;38:554-557.Crossref 3. Chui HC, Teng EL, Henderson VW, Moy AC. Clinical subtypes of dementia of the Alzheimer type . Neurology . 1985;35:1544-1550.Crossref 4. Drevets WC, Rubin EH. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer's type . Biol Psychiatry . 1989;25:38-48.Crossref 5. Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer's disease . Am J Psychiatry . 1989;146:577-587. 6. Duffy P, Mayeux R, Kupsky W. Familial Alzheimer's disease with myoclonus and spongy change . Arch Neurol . 1988;45:1097-1103.Crossref 7. Kaye JA, May C, Atack JR, et al. Cerebrospinal fluid neurochemistry in the myoclonic subtype of Alzheimer's disease . Ann Neurol . 1988;24:647-650.Crossref 8. Stern Y, Mayeux R, Sano M, Hauser WA, Bush T. Predictors of disease course in patients with probable Alzheimer's disease . Neurology . 1987;37:1649-1653.Crossref 9. Stern Y, Mayeux R, Hesdorffer D, Sano M. Measurement and prediction of functional capacity in Alzheimer's disease . Neurology . 1990;40:8-14.Crossref 10. Stern Y, Mayeux R, Chen JY, Sano M. Predictors of mortality in Alzheimer's disease . Ann Neurol . 1989;26:132. 11. Kaplan EL, Meier P. Nonparametricestimation from incomplete observations . J Am Stat Assoc . 1958;53:457-481.Crossref 12. Diagnostic and Statistical Manual of Mental Disorders-III-Revised . Washington, DC: American Psychiatric Association; 1986. 13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease . Neurology . 1984;34:939-944.Crossref 14. Fahn S, Marsden C, Calne D, et al. Recent Developments in Parkinson's Disease . Florham Park, NJ: Macmillan Healthcare Information; 1987;2:153-163. 15. Sano M, Stern Y, Mayeux R, Hartman S, Devanand DP. A standardized technique for establishing the onset symptoms of probable Alzheimer's disease J Exp Clin Neuropsychol . 1987;9:65. Abstract. 16. Lee E. Statistical Methods for Survival Data Analysis . Belmont, Calif: Lifetime Learning Publications; 1980. 17. SAS User's Guide. Statistics. 5 ed. Cary, NC: SAS Institute Inc; 529-557. 18. Rothman KJ. Modern Epidemiology . Boston, Mass: Little Brown & Co Inc; 1986. 19. Ditter SM, Mirra SS. Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients . Neurology . 1987;37:754-760.Crossref 20. Molsa PK, Marttila RJ, Rinne UK. Extrapyramidal signs in Alzheimer's disease . Neurology . 1984;34:1114-1116.Crossref 21. Pearce J. The extrapyramidal disorder of Alzheimer's disease . Eur Neurol . 1974;12:94-103.Crossref 22. National Institutes of Health Conference. Alzheimer's disease: clinical and biological heterogeneity . Ann Intern Med . 1988;109:298-311.Crossref 23. Breitner JCS, Murphy EA, Silverman JM, Mohs RC, David KL. Age-dependent expression of familial risk in Alzheimer's disease . Am J Epidemiol . 1988;128:536-548. 24. Farrer LA, Myers RH, Cupples LA, et al. Transmission and age-at-onset patterns in familial Alzheimer's disease: evidence for heterogeneity . Neurology . 1990;40:395-403.Crossref

Journal

Archives of NeurologyAmerican Medical Association

Published: Nov 1, 1991

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$499/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month